• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰岛素的使用与慢性肢体缺血的糖尿病患者肢体保存和生存不良有关。

Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia.

机构信息

Division of Vascular Surgery, Veterans' Administration Western New York Healthcare System, Buffalo, NY, USA.

出版信息

J Vasc Surg. 2010 May;51(5):1178-89; discussion 1188-9. doi: 10.1016/j.jvs.2009.11.077. Epub 2010 Mar 20.

DOI:10.1016/j.jvs.2009.11.077
PMID:20304581
Abstract

OBJECTIVE

The goal was to compare the outcomes in patients with disabling claudication (DC) or critical limb ischemia (CLI) to determine if diabetics (DM) have poorer patency, limb salvage (LS), and survival rates than nondiabetic patients and if the diabetic regimen affects these outcomes.

METHODS

All patients who presented with DC or CLI between June 2001 and September 2008 were included. Non-DM patients were compared with those with DM who are currently managed by diet only or oral medications (D-OM), oral medications plus insulin (OM+INS), or insulin alone (INS).

RESULTS

Of the 746 patients (886 limbs), there were 406 patients (464 limbs) in non-DM, 96 patients (135 limbs) in D-OM, 98 patients (118 limbs) in OM+INS, and 146 patients (185 limbs) in INS groups. There were more patients with coronary artery disease, hypertension, and renal insufficiency in the DM group than non-DM, with the INS group having the highest incidence of renal insufficiency/dialysis (46%/20%). Gangrene and foot sepsis were significantly more frequent in patients in OM+INS (45%/3%) and INS (50%/6%) than non-DM (15%/0.2%) and D-OM groups (25%/1%; P < .001). More patients in the INS group (14%) and OM+INS (9%) had primary amputation than non-DM (4%) and D-OM (4%; P < .01). Mean follow-up was 26.3 +/- 20.7 months. Overall survival following revascularization was similar in D-OM and non-DM and OM+INS and INS, the latter being significantly worse (P < .001). The LS rate in D-OM and non-DM was also identical, whereas OM-INS and INS had significantly worse LS, with OM-INS marginally better than INS (P = .094). Primary patency (PP) was worse in endovascular-treated patients on insulin than non-DM and D-OM patients (P < .001), whereas PP was similar between groups in open-treated patients. Multivariate analysis showed that coronary artery disease, renal insufficiency, chronic obstructive pulmonary disease, indication for intervention, insulin use, nonambulatory status, and statin drug non-use were independently associated with decreased survival, whereas insulin use, presence of gangrene, need for infrapopliteal interventions, and nonambulatory status were independently associated with limb loss. TransAtlantic Inter-Society Consensus (TASC) classification of the treated lesions being C or D, infrapopliteal interventions, and indication of intervention (DC vs CLI) were independently associated with primary patency, whereas insulin use was not.

CONCLUSIONS

Diabetic patients who present with limb ischemia can be subdivided into three distinct subgroups based on their diabetic regimen. The survival and LS rates of those controlled with diet or OM are nearly identical to nondiabetics, both of which are significantly better than OM+INS or INS. The PP rate in endovascular-treated patients is worse in patients who are on insulin. Being on insulin is independently associated with decreased survival and limb loss but not PP.

摘要

目的

比较有严重跛行(DC)或严重肢体缺血(CLI)的患者的结局,以确定糖尿病(DM)患者的通畅率、保肢率(LS)和生存率是否比非糖尿病患者差,以及糖尿病的治疗方案是否会影响这些结局。

方法

纳入 2001 年 6 月至 2008 年 9 月期间出现 DC 或 CLI 的所有患者。将非 DM 患者与目前仅接受饮食或口服药物(D-OM)、口服药物加胰岛素(OM+INS)或单独胰岛素(INS)治疗的 DM 患者进行比较。

结果

在 746 例患者(886 条肢体)中,非 DM 组有 406 例患者(464 条肢体),D-OM 组 96 例患者(135 条肢体),OM+INS 组 98 例患者(118 条肢体),INS 组 146 例患者(185 条肢体)。DM 组的冠状动脉疾病、高血压和肾功能不全患者多于非 DM 组,INS 组肾功能不全/透析的发生率最高(46%/20%)。OM+INS 组(45%/3%)和 INS 组(50%/6%)的坏疽和足部感染发生率明显高于非 DM 组(15%/0.2%)和 D-OM 组(25%/1%)(均 P<0.001)。INS 组(14%)和 OM+INS 组(9%)的患者中,原发性截肢的比例高于非 DM 组(4%)和 D-OM 组(4%)(均 P<0.01)。平均随访时间为 26.3±20.7 个月。血管重建后的总生存率在 D-OM 和非 DM 以及 OM+INS 和 INS 组之间相似,后者明显较差(P<0.001)。D-OM 和非 DM 组的 LS 率也相同,而 OM+INS 和 INS 组的 LS 率明显较差,OM+INS 组略好于 INS 组(P=0.094)。接受胰岛素治疗的腔内治疗患者的原发性通畅率(PP)明显差于非 DM 和 D-OM 患者(P<0.001),而开放治疗患者的 PP 在组间相似。多因素分析显示,冠状动脉疾病、肾功能不全、慢性阻塞性肺疾病、介入指征、胰岛素使用、非活动状态和他汀类药物不使用与生存率降低独立相关,而胰岛素使用、坏疽存在、需要进行膝下介入治疗和非活动状态与肢体丧失独立相关。接受治疗的病变 TASC 分类为 C 或 D、膝下介入治疗和介入指征(DC 与 CLI)与原发性通畅率独立相关,而胰岛素使用与原发性通畅率无关。

结论

出现肢体缺血的糖尿病患者可根据其糖尿病治疗方案分为三个不同亚组。用饮食或 OM 控制的患者的生存率和 LS 率与非糖尿病患者几乎相同,两者均明显优于 OM+INS 或 INS。接受腔内治疗的患者使用胰岛素时,PP 率较差。使用胰岛素与生存率降低和肢体丧失独立相关,但与 PP 无关。

相似文献

1
Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia.胰岛素的使用与慢性肢体缺血的糖尿病患者肢体保存和生存不良有关。
J Vasc Surg. 2010 May;51(5):1178-89; discussion 1188-9. doi: 10.1016/j.jvs.2009.11.077. Epub 2010 Mar 20.
2
Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions.糖尿病对股浅动脉腔内介入治疗结局的影响。
J Vasc Surg. 2007 Nov;46(5):946-958; discussion 958. doi: 10.1016/j.jvs.2007.06.047.
3
Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia.他汀类药物治疗与经腔内治疗严重肢体缺血后的临床结果改善相关。
J Vasc Surg. 2012 Feb;55(2):371-9; discussion 380. doi: 10.1016/j.jvs.2011.08.044. Epub 2011 Nov 1.
4
Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia.糖尿病患者经皮介入治疗后原发性通畅率降低是由于肢体威胁性缺血的发生率更高。
J Vasc Surg. 2008 Jan;47(1):101-8. doi: 10.1016/j.jvs.2007.09.018.
5
Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease.二甲双胍与外周动脉疾病血运重建术后生存率提高、心脏事件减少相关,且对通畅率和肢体挽救无影响。
Ann Vasc Surg. 2019 Feb;55:63-77. doi: 10.1016/j.avsg.2018.05.054. Epub 2018 Aug 4.
6
Functional status as a prognostic factor for primary revascularization for critical limb ischemia.功能状态作为临界肢体缺血患者初次血运重建的预后因素。
J Vasc Surg. 2010 Feb;51(2):360-71.e1. doi: 10.1016/j.jvs.2009.08.051.
7
Impact of chronic kidney disease on outcomes of superficial femoral artery endoluminal interventions.慢性肾脏病对股浅动脉腔内介入治疗结局的影响
Ann Vasc Surg. 2009 Sep-Oct;23(5):560-8. doi: 10.1016/j.avsg.2008.11.010. Epub 2009 Jan 6.
8
Outcomes after endovascular intervention for chronic critical limb ischemia.慢性肢体严重缺血血管内介入治疗的结果。
J Vasc Surg. 2011 Jun;53(6):1575-81. doi: 10.1016/j.jvs.2011.01.068. Epub 2011 Apr 22.
9
Improved outcomes are associated with multilevel endovascular intervention involving the tibial vessels compared with isolated tibial intervention.与单纯的胫血管介入治疗相比,涉及胫血管的多级血管内介入治疗可带来更好的治疗效果。
J Vasc Surg. 2009 Mar;49(3):638-43; discussion 643-4. doi: 10.1016/j.jvs.2008.10.021.
10
Perioperative outcomes and amputation-free survival after lower extremity bypass surgery in California hospitals, 1996-1999, with follow-up through 2004.1996 - 1999年加利福尼亚州医院下肢搭桥手术后的围手术期结果及无截肢生存率,随访至2004年。
J Vasc Surg. 2009 Oct;50(4):776-783.e1. doi: 10.1016/j.jvs.2009.05.050. Epub 2009 Jul 12.

引用本文的文献

1
Chronic limb threatening ischemia and diabetes mellitus: the severity of tibial atherosclerosis and outcome after infrapopliteal revascularization.慢性肢体威胁性缺血和糖尿病:胫动脉粥样硬化的严重程度和腘动脉以下血运重建后的结果。
Scand J Surg. 2021 Dec;110(4):472-482. doi: 10.1177/1457496920968679. Epub 2020 Nov 23.
2
Long-Term Effectiveness and Safety of Initiating Statin Therapy After Index Revascularization In Patients With Peripheral Arterial Occlusive Disease.索引血运重建后起始他汀类药物治疗对周围动脉阻塞性疾病患者的长期疗效和安全性。
J Am Heart Assoc. 2020 Nov 17;9(22):e018338. doi: 10.1161/JAHA.120.018338. Epub 2020 Nov 13.
3
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
与二肽基肽酶-4(DPP-4)抑制剂单药治疗相比,DPP-4抑制剂与胰岛素联合治疗并不能进一步降低糖尿病足患者发生心血管事件的风险:一项基于全国人口的研究。
Diabetol Metab Syndr. 2018 Oct 17;10:75. doi: 10.1186/s13098-018-0378-6. eCollection 2018.
4
Open and Endovascular Treatment of Trans-Atlantic Inter-Society Consensus II D Aortoiliac Occlusive Lesions: What Determines the Rate of Restenosis?《跨大西洋跨学会共识II D型主髂动脉闭塞性病变的开放手术与血管腔内治疗:什么决定了再狭窄率?》
Chin Med J (Engl). 2015 Nov 20;128(22):3035-42. doi: 10.4103/0366-6999.169053.
5
Influence of risk factors and comorbidities on the successful therapy and survival of patients with critical limb ischemia.危险因素和合并症对严重肢体缺血患者成功治疗及生存的影响。
Clujul Med. 2013;86(1):57-64. Epub 2013 Feb 4.
6
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.在ACCORD试验中的胰岛素剂量与心血管死亡率
Diabetes Care. 2015 Nov;38(11):2000-8. doi: 10.2337/dc15-0598. Epub 2015 Oct 13.
7
Diagnoses and clinical features associated with high risk for unplanned readmission in vascular surgery. A cohort study.血管外科计划外再入院高风险相关的诊断与临床特征。一项队列研究。
Ann Med Surg (Lond). 2015 Apr 14;4(2):124-8. doi: 10.1016/j.amsu.2015.04.005. eCollection 2015 Jun.
8
Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study.空腹血糖受损、糖尿病及其管理与外周动脉疾病的表现和结局的关联:一项队列研究
Cardiovasc Diabetol. 2014 Nov 1;13:147. doi: 10.1186/s12933-014-0147-2.
9
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.关于外周动脉疾病更具盈利性策略的系统评价和荟萃分析。
Ann Med. 2014 Nov;46(7):475-89. doi: 10.3109/07853890.2014.932618. Epub 2014 Jul 21.